Clinical Trial Update: CD22 Redirected Autologous T Cells for ALL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on autologous T cells redirected to CD22 for B-cell leukemias and lymphomas, sponsored by the University of Pennsylvania; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CD22-directed autologous CAR-T cells (CD22-targeted CAR-T cell therapy)

Snippet

Sponsor: University of Pennsylvania | Conditions: B Cell Leukemias, B Cell Lymphomas | Phase 1 | Status: ACTIVE_NOT_RECRUITING